相关实验视频

Updated: Jul 20, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

在哈萨克斯坦的HIV-1亚型A6和CRF02_AG中存在高水平的抗药性突变

Ainur Sanaubarova¹, Emma Pujol-Hodge², Natalya Dzissyuk³

¹Department of Biomedical Sciences, Nazarbayev School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.

|July 29, 2023

概括

哈萨克斯坦的艾滋病毒耐药性很高,32%的艾滋病毒感染者表现出耐药性. 不同的艾滋病毒亚型具有明显的耐药突变,突出显示需要监测和查.

科学领域:

* 病毒学病毒学
* 分子流行病学
* * 公共卫生公共卫生

背景情况:

*哈萨克斯坦的艾滋病毒发病率从2010年到2020年增加了73%.
* 据估计,在2020年,哈萨克斯坦约有3.5万人感染艾滋病毒 (PLHIV).
* 关于哈萨克斯坦抗逆转录病毒药物耐药性 (ADR) 患病率的数据有限.

研究的目的:

* 调查哈萨克斯坦艾滋病毒的分子流行病学.
* 确定抗逆转录病毒药物耐药性 (ADR) 的流行率和模式.
* 分析亚型分布,并识别耐药突变 (DRM).

主要方法:

*从PLHIV (2017-2020) 中分析了968个部分HIV-1pol序列.
* 测序覆盖了哈萨克斯坦近3%的PLHIV.
*进行了家族遗传学分析和子使用分析.

主要成果:

*艾滋病毒亚型A6 (57%) 和CRF02_AG (41%) 主导.
*32%的序列表现出高水平的耐药性.
*观察到不同的DRM:A6与A62V,G190S,K101E,D67N相关;CRF02_AG与K103N,V179E相关.
* 遗传学分析表明A62V的持续传播.

结论:

*哈萨克斯坦的艾滋病毒流行病的特点是高水平的耐药性.
*在A6和CRF02_AG亚型之间存在不同的DRM频率.
* 常规药物耐药性监测和亚型/DRM查对于有效的ART至关重要.

关键词:

A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 A6 在CRF02_AG中,您可以使用CRF02_AG.中亚的中亚地区.这些DRM是DRM.艾滋病病毒艾滋病病毒艾滋病病毒哈萨克斯坦哈萨克斯坦哈萨克斯坦抗逆转录病毒药物耐药性抗逆转录病毒药物耐药性分子流行病学分子流行病学人类遗传学遗传学

更多相关视频

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...